

From: [John Wiley](#)
 To: [John Wiley](#)
 CC: [John Wiley](#)
 Subject: [John Wiley](#)
 Date: [John Wiley](#)

EXTERNAL MESSAGE: Do not open attachments or click on links unless you recognize and trust the sender. Help: Please see the attached 30 Day Pricing for Novartis Drug ADARVEGO. Please confirm receipt of this information. Thank you!

Product Name	NDC	DRUG_PCODE_DESC	INTRODUCED_TO_MARKET_DATE	WAC_AT_INTRODUCTION	MARKETING_PRICING_PLAN	MARKETING_PRICING_NONPUBLIC	ESTIMATED PATIENTS IN THE UNITED STATES WITH A CONDITION FOR WHICH THE NEW PRESCRIPTION DRUG MAY BE PRESCRIBED	BREAKTHROUGH_THERAPY_INDICATOR	PRIORITY_REVIEW_INDICATOR	ACQUISITION_DATE	ACQUISITION_PRICE	ACQUISITION_PRICE_NONPUBLIC	ACQUISITION_PRICE_COMMENT	GENERAL_COMMENTS
ADARVEGO*	00076-0885-61	ADARVEGO® (enzamitrombimab) injection is a sterile, clear to opalescent, colorless to slightly hazy, slightly yellow solution for intravenous infusion supplied as: Carton containing one 100 mg/10 mL (10 mg/mL) single-dose vial NDC 00076-0885-61. The single-dose vial has a rubber stopper and an aluminum cap with a plastic flip-off disk. Each 10 mL vial is made of Type I glass.	11.18.2019	\$1,307.34	Novartis considered many factors in determining the price of Adarvego® including the value the medicine brings to the patient population, the healthcare system, and society. Adarvego® is the first targeted therapy to prevent the painful vaso-occlusive event (VOC) that patients with sickle cell disease endure. We believe Adarvego® is poised to reduce the burden of VOCs on patients with sickle cell disease, caregivers, the US healthcare system and society as a whole. We are focused on access to Adarvego® for this patient population. For marketing, we anticipate multi-channel advertising & promotion for Adarvego®.	N/A	1,308	Yes	Yes	11/18/2019	\$65M		Regeneron Pharmaceuticals Corporation, formerly known as Solvay Pharmaceutical Corporation, was acquired by Novartis for \$65M. The product was a part of the portfolio acquired by Novartis.	We believe that all information submitted by Novartis to the Department of Vermont Health Access or to the Attorney General under Vt. Stat. tit. 18 § 462C or 4617, including all information contained in this submission, is confidential and proprietary commercial or financial information not subject to disclosure, including under the Vermont Public Records Act (Subchapter 3 of Chapter 5 of the Vermont Statutes) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis' related information herein be maintained to the maximum extent permitted by law. To the extent that any of this designated information is requested, whether under Vermont Public Records Act (Subchapter 3 of Chapter 5 of the Vermont Statutes) or otherwise, we request that Novartis be notified of the request and afforded the opportunity to submit objections to disclosure.

James Mackay
 Assistant Director, Government Pricing
 Phone: +1 802 261 4026
james.mackay@novartis.com
Manager Market Finance/HCA
 Novartis Pharmaceuticals
 One Health Plaza
 East Hanover, NJ 07930-1080
 USA